In human breast cancers, tumor infiltration by tumor associated macrophages (TAMs) correlates with multiple markers of poor prognosis: higher tumor macrophage counts are associated with higher tumor grade, higher tumor vascular density, and reduced overall survival\[[@B1]\]. TAMs secrete biologically active molecules that promote tumor growth and metastasis\[[@B1]\]. Additionally, unique subpopulations of TAMs contribute to the immunosuppressive microenvironment that significantly enhances tumor genesis by limiting vital anti-tumor immune responses\[[@B2]\], however the mechanisms that regulate TAM development and their actions within the tumor microenvironment remain poorly understood. Pre-clinical studies demonstrate that macrophage ablation retards tumor progression\[[@B3]\], suggesting that TAMs may be a viable target for eliciting an anti-tumor response. We have therefore begun to analyze the effects of novel cannabinoid agonists on TAMs in a murine model of breast cancer. Macrophage expression of cannabinoid receptor 2 (CB~2~) is induced by inflammatory stimuli and regulates multiple functions including chemotaxis and antigen presentation\[[@B4]\]. Recent findings in our lab and by others indicate that CB~2~ agonists significantly reduce tumor burden and metastasis in several models. Although the *in vivo* anti-tumor efficacy of cannabinoids is mimicked in continuously cultured cancer cells *in vitro*, cannabinoid potency for direct elicitation of apoptosis in cancer cells is far lower, indicating that other mechanisms (perhaps other cell types within the tumor) are involved *in vivo*. We have recently obtained evidence that: 1) CB~2~ agonists mediate inhibition of primary tumor growth and metastasis *in vivo*, 2) significant infiltration of TAMs occurs within the developing tumor in this murine model, 3) administration of a CB~2~ agonist increases populations of pro-inflammatory M1 macrophages (MHC Class II-high, iNOS high) in both the primary tumor and in the spleen of tumor bearing mice, and 4) a concurrent increase in the proportion of CD8+ cytotoxic T lymphocytes is also observed within the primary tumor upon CB~2~ agonist treatment.
